Johnson & Johnson (JNJ) News Today

Johnson & Johnson (NYSE: JNJ) shares have decreased despite encouraging pipeline updates. The stock recently traded below its 50-day moving average, although it remains well above its 200-day average and is up substantially over the past year. The main focus today is whether new drug launches can offset the expected decline in Stelara revenue.

• Positive Sentiment: ICOTYDE delivers durable psoriasis results: New Phase 3 ICONIC-TOTAL data showed sustained skin clearance through two years. At Week 112, 70% of patients achieved clear or almost clear skin, while complete clearance reached 89% for genital psoriasis and 60% for scalp psoriasis, with no new safety concerns reported. The results support ICOTYDE as a potential important first-line systemic treatment and strengthen J&J’s immunology pipeline. J&J ICOTYDE psoriasis data
• Positive Sentiment: Innovative Medicine growth remains a key offset: Analysts expect oncology products and newer launches to drive another quarter of growth, helping counter revenue erosion from Stelara biosimilars. This supports the investment case that J&J can replace lost exclusivity revenue with newer products. Innovative Medicine Q3 growth drivers
• Positive Sentiment: IMAAVY adds pipeline support: New data in generalized myasthenia gravis gives investors additional evidence that J&J’s immunology portfolio could provide future growth beyond current blockbuster medicines. IMAAVY data update
• Neutral Sentiment: J&J continues to receive favorable valuation commentary and analyst support after a strong one-year advance, but its approximately 30-times earnings valuation leaves less room for disappointment.
• Negative Sentiment: Stelara biosimilar pressure remains the central risk: The expected decline in Stelara sales is weighing on near-term growth comparisons and may be contributing to investor caution despite positive pipeline news.